IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.799
AS - Asia 6.273
EU - Europa 3.184
SA - Sud America 1.480
Continente sconosciuto - Info sul continente non disponibili 365
AF - Africa 140
OC - Oceania 21
Totale 22.262
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.344
SG - Singapore 2.833
IT - Italia 1.549
CN - Cina 1.423
BR - Brasile 1.097
VN - Vietnam 643
IN - India 622
SE - Svezia 406
GB - Regno Unito 383
CA - Canada 305
DE - Germania 283
HK - Hong Kong 160
AR - Argentina 136
FI - Finlandia 110
BD - Bangladesh 109
ID - Indonesia 84
EC - Ecuador 72
MX - Messico 71
NL - Olanda 69
RU - Federazione Russa 54
FR - Francia 53
IQ - Iraq 52
UA - Ucraina 45
CO - Colombia 43
PK - Pakistan 43
ES - Italia 40
JP - Giappone 40
RO - Romania 40
JO - Giordania 35
ZA - Sudafrica 35
CL - Cile 32
PY - Paraguay 32
SA - Arabia Saudita 31
VE - Venezuela 30
TR - Turchia 29
PL - Polonia 27
EG - Egitto 24
EU - Europa 22
IR - Iran 22
PE - Perù 21
CZ - Repubblica Ceca 20
CR - Costa Rica 18
LT - Lituania 17
AE - Emirati Arabi Uniti 15
AT - Austria 15
IE - Irlanda 15
MA - Marocco 15
AU - Australia 14
HN - Honduras 14
MY - Malesia 14
KE - Kenya 13
KR - Corea 13
UY - Uruguay 13
UZ - Uzbekistan 13
IL - Israele 11
TN - Tunisia 11
KZ - Kazakistan 10
PT - Portogallo 10
GT - Guatemala 9
JM - Giamaica 9
PH - Filippine 9
AZ - Azerbaigian 8
EE - Estonia 8
ET - Etiopia 8
LB - Libano 8
NG - Nigeria 8
CH - Svizzera 7
DZ - Algeria 7
SN - Senegal 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
NI - Nicaragua 6
NP - Nepal 6
TT - Trinidad e Tobago 6
CY - Cipro 5
PR - Porto Rico 5
PS - Palestinian Territory 5
TW - Taiwan 5
NZ - Nuova Zelanda 4
SC - Seychelles 4
AL - Albania 3
BN - Brunei Darussalam 3
GE - Georgia 3
GR - Grecia 3
HR - Croazia 3
HU - Ungheria 3
KG - Kirghizistan 3
KW - Kuwait 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
OM - Oman 3
PA - Panama 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
GY - Guiana 2
KI - Kiribati 2
Totale 21.900
Salva come PNG Salva come JPEG
Città #
San Jose 2.029
Ashburn 1.003
Chandler 906
Singapore 890
Santa Clara 536
Dallas 521
Council Bluffs 438
Hefei 429
Bengaluru 428
Milan 408
Princeton 390
Lawrence 383
Chicago 286
Beijing 258
London 255
Ho Chi Minh City 252
Wilmington 224
Munich 211
Ottawa 165
Catanzaro 158
Hong Kong 145
Hanoi 125
Los Angeles 116
Des Moines 111
New York 103
São Paulo 95
Boardman 85
Phoenix 83
Rome 75
Turku 73
Shanghai 51
Naples 47
Rio de Janeiro 44
Guangzhou 42
Pune 40
Helsinki 36
Montreal 35
The Dalles 34
San Francisco 33
Brooklyn 32
Norwalk 32
Haiphong 30
Redwood City 30
Atlanta 28
Redmond 28
Amman 27
Boston 27
Tokyo 27
Da Nang 26
Chennai 25
Biên Hòa 24
Quito 24
Orem 23
Warsaw 23
Denver 21
Manchester 21
Parma 21
Baghdad 20
Columbus 20
Buffalo 19
Curitiba 19
Mexico City 19
Jeddah 18
Seattle 18
Stockholm 18
Thái Bình 18
Guayaquil 17
Salvador 17
Washington 17
Charlotte 16
San Nicola Manfredi 16
Toronto 16
Aversa 15
Delhi 15
Dhaka 15
Porto Alegre 15
Amsterdam 14
Olomouc 14
Reggio Calabria 14
San José 14
West Jordan 14
Brasília 13
Campinas 13
Frankfurt am Main 13
Horia 13
Johannesburg 13
Madrid 13
Mountain View 13
Palermo 13
Tashkent 13
Bari 12
Belo Horizonte 12
Bologna 12
Buenos Aires 12
Carbonia 12
Houston 12
Las Vegas 12
Montevideo 12
Nairobi 12
Recife 12
Totale 12.647
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 506
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 154
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 129
miR-22 suppresses DNA ligase III addiction in multiple myeloma 116
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 109
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 106
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 103
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 101
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 99
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 99
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 98
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 97
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 96
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 94
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 92
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 91
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 90
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 90
277 POSTER An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 89
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 89
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 88
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 87
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 86
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 86
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 86
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 84
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 84
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 84
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 84
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 83
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 82
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 82
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 81
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 81
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 81
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 80
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 80
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 80
Mir-34: a new weapon against cancer? 79
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 79
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 79
Genes specifically expressed during early stages of haemopoietic differentiation detected by DDRT-PCR. 79
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 79
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 79
Fetal ontogeny and tumor expression of the early thymic antigen UN1 78
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 78
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 78
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 77
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 77
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 77
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 76
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 76
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 75
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 75
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 74
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 74
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 74
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 74
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 74
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 73
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 73
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 73
Anti-myeloma activity of miR-125 mimics 73
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 71
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 70
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 70
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 70
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 70
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 70
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 69
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 69
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 69
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 69
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 68
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 68
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 68
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 67
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 67
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 67
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 67
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 67
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 66
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study 66
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 65
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 65
Mir-221/222 are promising targets for innovative anticancer therapy 65
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 65
Transcriptional regulation of the mismatch repair gene hMLH1 65
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 64
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 64
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 63
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 63
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 63
miR-221/222 inhibitors for the treatment of multiple myeloma 63
Liposomes containing zoledronic acid: A new opportunity against cancer 63
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 63
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 63
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 63
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 62
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 62
Totale 8.299
Salva come PNG Salva come JPEG
Categoria #
all - tutte 216.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 216.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.101 0 0 0 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20269.335 454 966 1.028 1.709 916 362 1.222 549 1.072 635 265 157
2026/20272.031 122 473 960 476 0 0 0 0 0 0 0 0
Totale 22.262